Literature DB >> 30820837

A Vesicular Stomatitis Virus-Based Vaccine Carrying Zika Virus Capsid Protein Protects Mice from Viral Infection.

Xiaodan Shi1, Jingping Hu1, Jing Guo1, Chuanjian Wu1, Sidong Xiong2, Chunsheng Dong3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30820837      PMCID： PMC6420591          DOI： 10.1007/s12250-019-00083-7

Source DB:  PubMed          Journal:  Virol Sin        ISSN： 1995-820X            Impact factor:   4.327


× No keyword cloud information.
  30 in total

1.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

2.  The structural basis for serotype-specific neutralization of dengue virus by a human antibody.

Authors:  Ee Ping Teoh; Petra Kukkaro; En Wei Teo; Angeline P C Lim; Tze Tong Tan; Andy Yip; Wouter Schul; Myint Aung; Victor A Kostyuchenko; Yee Sin Leo; Soh Ha Chan; Kenneth G C Smith; Annie Hoi Yi Chan; Gang Zou; Eng Eong Ooi; D Michael Kemeny; Grace K Tan; Jowin K W Ng; Mah Lee Ng; Sylvie Alonso; Dale Fisher; Pei-Yong Shi; Brendon J Hanson; Shee-Mei Lok; Paul A MacAry
Journal:  Sci Transl Med       Date:  2012-06-20       Impact factor: 17.956

3.  A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus.

Authors:  Laura Lazo; Lisset Hermida; Aída Zulueta; Jorge Sánchez; Carlos López; Ricardo Silva; Gerardo Guillén; María G Guzmán
Journal:  Vaccine       Date:  2006-10-09       Impact factor: 3.641

4.  Attenuated vesicular stomatitis viruses as vaccine vectors.

Authors:  A Roberts; L Buonocore; R Price; J Forman; J K Rose
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.

Authors:  Steven M Jones; Heinz Feldmann; Ute Ströher; Joan B Geisbert; Lisa Fernando; Allen Grolla; Hans-Dieter Klenk; Nancy J Sullivan; Viktor E Volchkov; Elizabeth A Fritz; Kathleen M Daddario; Lisa E Hensley; Peter B Jahrling; Thomas W Geisbert
Journal:  Nat Med       Date:  2005-06-05       Impact factor: 53.440

6.  Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.

Authors:  Jon D Reuter; Beatriz E Vivas-Gonzalez; Daniel Gomez; Jean H Wilson; Janet L Brandsma; Heather L Greenstone; John K Rose; Anjeanette Roberts
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Joan B Geisbert; Douglas S Reed; Friederike Feldmann; Allen Grolla; Ute Ströher; Elizabeth A Fritz; Lisa E Hensley; Steven M Jones; Heinz Feldmann
Journal:  Vaccine       Date:  2008-10-18       Impact factor: 3.641

9.  A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice.

Authors:  Melissa A Cobleigh; Xin Wei; Michael D Robek
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

10.  Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.

Authors:  Sagar U Kapadia; John K Rose; Elaine Lamirande; Leatrice Vogel; Kanta Subbarao; Anjeanette Roberts
Journal:  Virology       Date:  2005-09-30       Impact factor: 3.616
View more
  4 in total

Review 1.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

Review 2.  Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens.

Authors:  Anahita Fathi; Christine Dahlke; Marylyn M Addo
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

3.  Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.

Authors:  Xiang-Wei Kong; Xiao Zhang; Guo-Long Bu; Hui-Qin Xu; Yin-Feng Kang; Cong Sun; Qian-Ying Zhu; Run-Bo Ma; Zheng Liu; Yi-Xin Zeng; Mu-Sheng Zeng; Zhu-Long Hu
Journal:  J Virol       Date:  2022-04-11       Impact factor: 6.549

Review 4.  Structure and function of capsid protein in flavivirus infection and its applications in the development of vaccines and therapeutics.

Authors:  Xingcui Zhang; Yanting Zhang; Renyong Jia; Mingshu Wang; Zhongqiong Yin; Anchun Cheng
Journal:  Vet Res       Date:  2021-06-30       Impact factor: 3.683
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.